Palena C - Search Results

1

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.

Dahut M, Fousek K, Horn LA, Angstadt S, Qin H, Hamilton DH, Schlom J, Palena C. Dahut M, et al. Among authors: palena c. J Immunother Cancer. 2023 Sep;11(9):e007386. doi: 10.1136/jitc-2023-007386. J Immunother Cancer. 2023. PMID: 37678915 Free PMC article.

2

Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.

Palena C, Hamilton DH. Palena C, et al. Adv Cancer Res. 2015;128:69-93. doi: 10.1016/bs.acr.2015.04.001. Epub 2015 May 12. Adv Cancer Res. 2015. PMID: 26216630 Free PMC article. Review.

3

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.

Horn LA, Riskin J, Hempel HA, Fousek K, Lind H, Hamilton DH, McCampbell KK, Maeda DY, Zebala JA, Su Z, Schlom J, Palena C. Horn LA, et al. Among authors: palena c. J Immunother Cancer. 2020 Mar;8(1):e000326. doi: 10.1136/jitc-2019-000326. J Immunother Cancer. 2020. PMID: 32188703 Free PMC article.

4

Tumor Plasticity and Resistance to Immunotherapy.

Horn LA, Fousek K, Palena C. Horn LA, et al. Among authors: palena c. Trends Cancer. 2020 May;6(5):432-441. doi: 10.1016/j.trecan.2020.02.001. Epub 2020 Mar 4. Trends Cancer. 2020. PMID: 32348738 Free PMC article. Review.

5

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).

Bilusic M, McMahon S, Madan RA, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marté JL, Floudas C, Strauss J, Redman J, Abdul Sater H, Rabizadeh S, Soon-Shiong P, Schlom J, Gulley JL. Bilusic M, et al. Among authors: palena c. J Immunother Cancer. 2021 Mar;9(3):e002374. doi: 10.1136/jitc-2021-002374. J Immunother Cancer. 2021. PMID: 33762322 Free PMC article. Clinical Trial.

6

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.

Minnar CM, Chariou PL, Horn LA, Hicks KC, Palena C, Schlom J, Gameiro SR. Minnar CM, et al. Among authors: palena c. J Immunother Cancer. 2022 Jun;10(6):e004561. doi: 10.1136/jitc-2022-004561. J Immunother Cancer. 2022. PMID: 35764364 Free PMC article.

7

Cancer vaccines: preclinical studies and novel strategies.

Palena C, Abrams SI, Schlom J, Hodge JW. Palena C, et al. Adv Cancer Res. 2006;95:115-45. doi: 10.1016/S0065-230X(06)95004-0. Adv Cancer Res. 2006. PMID: 16860657 Review.

8

New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.

Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen PM, Yokokawa J, Pastan I, Schlom J, Tsang KY. Cereda V, et al. Among authors: palena c. Cancer Immunol Immunother. 2010 Jan;59(1):63-71. doi: 10.1007/s00262-009-0723-6. Epub 2009 Jun 4. Cancer Immunol Immunother. 2010. PMID: 19495750 Free PMC article.

9

Vaccines against human carcinomas: strategies to improve antitumor immune responses.

Palena C, Schlom J. Palena C, et al. J Biomed Biotechnol. 2010;2010:380697. doi: 10.1155/2010/380697. Epub 2010 Mar 16. J Biomed Biotechnol. 2010. PMID: 20300434 Free PMC article. Review.

10

IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. Fernando RI, et al. Among authors: palena c. Cancer Res. 2011 Aug 1;71(15):5296-306. doi: 10.1158/0008-5472.CAN-11-0156. Epub 2011 Jun 8. Cancer Res. 2011. PMID: 21653678 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

90 results

Search Page